Atara Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on June 17, 2024. The filing reports a corporate action approved by the Board of Directors regarding the Company's capital structure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than periodic financial performance.
Material Changes
The primary material change is the approval of a one-for-twenty-five reverse stock split of the Company's common stock. Key details include:
- Effective Date: Expected to become effective on June 20, 2024, at 12:01 a.m. Eastern Time.
- Trading: Shares will begin trading on a split-adjusted basis at the market open on June 20, 2024.
- Conversion Ratio: Every 25 shares of common stock issued and outstanding will be converted into 1 share.
- Fractional Shares: Stockholders will receive cash in lieu of any fractional shares.
- Adjustments: Proportionate adjustments will be made to outstanding equity awards, equity incentive plans, and pre-funded common stock warrants, including exercise or conversion prices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the mechanics of the reverse stock split. The document incorporates a press release (Exhibit 99.1) for further details on the announcement.
Investor Verification Checklist
- Confirm the exact effective time of the reverse stock split (June 20, 2024, 12:01 a.m. ET).
- Verify the treatment of fractional shares and the cash payout mechanism.
- Review the impact of the split on existing equity awards and pre-funded warrants.
- Check the trading symbol (ATRA) on The Nasdaq Stock Market LLC for post-split trading adjustments.